Related Experiment Videos
Defining benefits and risks for SERMs in clinical trials and clinical practice
S R Johnson1, B K Dunn, M Anthony
1University of Iowa Colleges of Medicine and Public Health, Iowa City 52242, USA. susan-johnson@uiowa.edu
Annals of the New York Academy of Sciences
|January 25, 2002
Summary
Defining drug benefits and risks requires aligning clinical trial data with patient and practitioner perspectives. Incorporating community input and head-to-head trials can improve the clinical meaningfulness of Selective Estrogen Receptor Modulators (SERMs) research.
Area of Science:
- Pharmacology
- Clinical Trials
- Patient-Centered Care
Background:
- Discrepancies exist between statistical significance in clinical trials and clinical meaningfulness for practitioners and patients regarding drug benefits and risk-benefit ratios.
- Selective Estrogen Receptor Modulators (SERMs) research often faces challenges in translating trial findings into practical clinical application.
Purpose of the Study:
- To explore methods for enhancing the clinical meaningfulness of data from clinical trials, particularly for SERMs.
- To address the discordance between statistical significance and perceived clinical value in drug evaluation.
- To highlight the importance of patient and clinician input in defining meaningful benefits and acceptable risk-benefit ratios.
Main Methods:
- Discussion of strategies to solicit input from community clinicians and patients during clinical trial design.
- Emphasis on the need for head-to-head comparative trials of new drugs against established agents.
- Exploration of challenges in communicating complex scientific literature to patients in a relevant manner.
Main Results:
- Soliciting community input can yield more clinically meaningful data but may also introduce unrealistic expectations.
- Head-to-head comparator trials, supported by organizations like the NIH, are crucial for providing clinicians with relevant comparative information.
- Estrogen remains a benchmark in menopause-related condition trials and practice, posing a challenge for newer agents.
Conclusions:
- Integrating patient and clinician perspectives into clinical trial design is essential for assessing clinically meaningful benefits and acceptable risk-benefit profiles.
- Comparator trials are vital for informing clinical practice and aiding patient decision-making.
- Effective communication strategies are needed to bridge the gap between scientific evidence and individual patient needs in clinical practice.